Related references
Note: Only part of the references are listed.Rapidly increasing rates of hip fracture in Beijing, China
Wei-Bo Xia et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline
Nelson B. Watts et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
The potential impact of the National Osteoporosis Foundation guidance on treatment eligibility in the USA: an update in NHANES 2005-2008
B. Dawson-Hughes et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Common allelic variants of the farnesyl diphosphate synthase gene influence the response of osteoporotic women to bisphosphonates
J. M. Olmos et al.
PHARMACOGENOMICS JOURNAL (2012)
Segmental copy-number gain within the region of isopentenyl diphosphate isomerase genes in sporadic amyotrophic lateral sclerosis
Takeo Kato et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Genetic Polymorphism of Geranylgeranyl Diphosphate Synthase (GGSP1) Predicts Bone Density Response to Bisphosphonate Therapy in Korean Women
Hyung Jin Choi et al.
YONSEI MEDICAL JOURNAL (2010)
Squalene synthase: a critical enzyme in the cholesterol biosynthesis pathway
R. Do et al.
CLINICAL GENETICS (2009)
International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions
E. Michael Lewiecki et al.
BONE (2008)
Modulatory effect of farnesyl pyrophosphate synthase (FDPS) rs2297480 polymorphism on the response to long-term amino-bisphosphonate treatment in postmenopausal osteoporosis
Francesca Marini et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Hip axis length changes in 10,554 males and females and the association with femoral neck fracture
Gao Gao et al.
JOURNAL OF CLINICAL DENSITOMETRY (2008)
Commentary: A revised clinician's guide to the prevention and treatment of osteoporosis
Bess Dawson-Hughes
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study
J. B. Richards et al.
LANCET (2008)
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy
R. G. G. Russell et al.
OSTEOPOROSIS INTERNATIONAL (2008)
PLINK: A tool set for whole-genome association and population-based linkage analyses
Shaun Purcell et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2007)
Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases
Rey-Ting Guo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
IDI2, a second lsopentenyl diphosphate isomerase in mammals
Daun B. Clizbe et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis
J. C. Gallagher et al.
BONE (2006)
Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years
Sydney Bonnick et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Recent advances in understanding the mechanism of action of bisphosphonates
Fraser P. Coxon et al.
CURRENT OPINION IN PHARMACOLOGY (2006)
Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis
SW Kim et al.
ENDOCRINE JOURNAL (2005)
BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial
S Palomba et al.
OSTEOPOROSIS INTERNATIONAL (2005)
Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of -1.6 to -2.5 at the femoral neck: The Fracture Intervention Trial
SA Quandt et al.
MAYO CLINIC PROCEEDINGS (2005)
Isopentenyl-diphosphate isomerases in human and mouse: Evolutionary analysis of a mammalian gene duplication
R Breitling et al.
JOURNAL OF MOLECULAR EVOLUTION (2003)
Effectiveness of alendronate treatment in postmenopausal women with osteoporosis: relationship with BsmI vitamin D receptor genotypes
S Palomba et al.
CLINICAL ENDOCRINOLOGY (2003)
Biomechanics of bone: Determinants of skeletal fragility and bone quality
CH Turner
OSTEOPOROSIS INTERNATIONAL (2002)
Colia1 Sp1 polymorphism predicts response of femoral neck bone density to cyclical etidronate therapy
AM Qureshi et al.
CALCIFIED TISSUE INTERNATIONAL (2002)
Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase
JD Bergstrom et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2000)
Predicting subsequent bone density response to intermittent cyclical therapy with etidronate from initial density response in patients with osteoporosis
RG Crilly et al.
OSTEOPOROSIS INTERNATIONAL (2000)
Share Paper
